Search results for " dose"

showing 10 items of 593 documents

An Acute Dose of Specific Grape and Apple Polyphenols Improves Endurance Performance: A Randomized, Crossover, Double-Blind versus Placebo Controlled…

2017

International audience; Polyphenols are thought to be an interesting ergogenic aid for exercise and recovery. However, most studies regarding the effects of polyphenols investigated several days of supplementations. The present work aimed to study the effects of an acute intake of grape and apple polyphenols on the capacity to maintain intense exercise, here named endurance performance. Forty-eight physically active men (31 ± 6 years) were included in this study. During the two testing sessions, volunteers completed an endurance test at a high percentage of their maximal aerobic power and time to exhaustion was measured. Respiratory and pain parameters were also monitored. The preceding eve…

0301 basic medicineAdultMalemedicine.medical_specialtycyclingEveningRandomizationTime FactorsPlacebo-controlled studylcsh:TX341-641PlaceboArticleDouble blind03 medical and health sciences0302 clinical medicineDouble-Blind Methodmaximal exertion; aerobic; cyclingMedicineHumansVitisAcute dose030109 nutrition & dieteticsNutrition and DieteticsCross-Over StudiesExercise Tolerancebusiness.industryPlant ExtractsPolyphenolsfood and beverages030229 sport sciencesRecovery of FunctionCrossover studyaerobicPolyphenolAnesthesiaFruitMalus[ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Physical therapyExercise Test[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Francebusinessmaximal exertionlcsh:Nutrition. Foods and food supplyFood Science
researchProduct

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric …

2021

Claudin 18.2 (CLDN18.2) is contained within normal gastric mucosa epithelial tight junctions; upon malignant transformation, CLDN18.2 epitopes become exposed. Zolbetuximab, a chimeric monoclonal antibody, mediates specific killing of CLDN18.2-positive cells through immune effector mechanisms.The FAST study enrolled advanced gastric/gastro-oesophageal junction and oesophageal adenocarcinoma patients (aged ≥18 years) with moderate-to-strong CLDN18.2 expression in ≥40% tumour cells. Patients received first-line epirubicin + oxaliplatin + capecitabine (EOX, arm 1, n = 84) every 3 weeks (Q3W), or zolbetuximab + EOX (loading dose, 800 mg/mIn the overall population, both PFS [hazard ratio (HR) = 0…

0301 basic medicineAdultmedicine.medical_specialtyAdolescentEsophageal NeoplasmsPopulationMedizinPhases of clinical researchAdenocarcinomaGastroenterologyLoading doseCapecitabine03 medical and health sciences0302 clinical medicineStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumanseducationCapecitabineeducation.field_of_studybusiness.industryHazard ratioAntibodies MonoclonalHematologyOxaliplatin030104 developmental biologyOncology030220 oncology & carcinogenesisClaudinsEsophagogastric Junctionbusinessmedicine.drugEpirubicinAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Novel iodoacetamido benzoheterocyclic derivatives with potent antileukemic activity are inhibitors of STAT5 phosphorylation

2016

Signal Transducer and Activator of Transcription 5 (STAT5) protein, a component of the STAT family of signaling proteins, is considered to be an attractive therapeutic target because of its involvement in the progression of acute myeloid leukemia. In an effort to discover potent molecules able to inhibit the phosphorylation-activation of STAT5, twenty-two compounds were synthesized and evaluated on the basis of our knowledge of the activity of 2-(3’,4’,5’-trimethoxybenzoyl)-3-iodoacetamido-6-methoxy benzo[b]furan derivative 1 as a potent STAT5 inhibitor. Most of these molecules, structurally related to compound 1, were characterized by the presence of a common 3’,4’,5’-trimethoxybenzoyl moi…

0301 basic medicineApoptosisAntineoplastic Agentchemistry.chemical_compoundBenzophenone0302 clinical medicinehemic and lymphatic diseasesFuranDrug DiscoverySTAT5 Transcription FactorTumor Cells CulturedThiopheneMoietyPhosphorylationSTAT5Molecular StructurebiologyChemistryBiological activityGeneral MedicineApoptosis; BCR/ABL expressing leukemia; In vitro antiproliferative activity; STAT5 inhibitors; Structure-activity relationship; Drug Discovery3003 Pharmaceutical Science; Organic Chemistry; PharmacologyLeukemia Myeloid Acute030220 oncology & carcinogenesisBCR/ABL expressing leukemiaApoptosis; BCR/ABL expressing leukemia; In vitro antiproliferative activity; STAT5 inhibitors; Structure-activity relationship; Antineoplastic Agents; Apoptosis; Benzofurans; Benzophenones; Cell Proliferation; Dose-Response Relationship Drug; Drug Screening Assays Antitumor; Humans; K562 Cells; Leukemia Myeloid Acute; Molecular Structure; Phosphorylation; STAT5 Transcription Factor; Structure-Activity Relationship; Tumor Cells Cultured; Drug Discovery3003 Pharmaceutical Science; Organic Chemistry; PharmacologyHumanStereochemistryAntineoplastic AgentsArticleNOBenzophenones03 medical and health sciencesK562 CellHumansStructure–activity relationshipBenzofuransCell ProliferationPharmacologyIndole testDose-Response Relationship DrugIn vitro antiproliferative activitySTAT5 inhibitorsDrug Discovery3003 Pharmaceutical ScienceOrganic ChemistryApoptosiSTAT5 inhibitorStructure-activity relationshipIn vitro030104 developmental biologybiology.proteinBenzofuranDrug Screening Assays AntitumorK562 Cells
researchProduct

Abstract OT1-08-04: A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients w…

2020

Abstract Background: Activating mutations in PIK3CA, encoding the p110α subunit of phosphatidylinositol 3-kinase (PI3K), are highly prevalent in breast cancer and solid tumor malignancies. GDC-0077 is a potent p110α-selective inhibitor with a novel mechanism of action that degrades mutant p110α and anti-tumor activity in PIK3CA-mutant breast cancer xenograft models as a single agent and in combination with anti-estrogens with or without a CDK4/6 inhibitor. An open-label, Phase I dose-escalation study of GDC-0077 monotherapy and GDC-0077 combined with endocrine therapies and palbociclib is underway in patients (pts) with locally advanced or metastatic PIK3CA-mutant solid tumors. Data from th…

0301 basic medicineCancer Researchmedicine.medical_specialtyCumulative dosebusiness.industryColorectal cancerCmaxPalbociclibmedicine.diseaseGastroenterology03 medical and health sciences030104 developmental biology0302 clinical medicineBreast cancerOncologyPharmacokinetics030220 oncology & carcinogenesisPharmacodynamicsInternal medicineMedicinebusinessAdverse effectCancer Research
researchProduct

Effects of Nandrolone Stimulation on Testosterone Biosynthesis in Leydig Cells

2016

Anabolic androgenic steroids (AAS) are among the drugs most used by athletes for improving physical performance, as well as for aesthetic purposes. A number of papers have showed the side effects of AAS in different organs and tissues. For example, AAS are known to suppress gonadotropin‐releasing hormone, luteinizing hormone, and follicle‐stimulating hormone. This study investigates the effects of nandrolone on testosterone biosynthesis in Leydig cells using various methods, including mass spectrometry, western blotting, confocal microscopy and quantitative real‐time PCR. The results obtained show that testosterone levels increase at a 3.9 μM concentration of nandrolone and return to the ba…

0301 basic medicineEnzymologicMalePhysiologyClinical BiochemistryAndrogenAnabolic Agents; Androgens; Animals; Cell Line; Cell Survival; Dose-Response Relationship Drug; Gene Expression Regulation Enzymologic; Leydig Cells; Male; Nandrolone; Phosphoproteins; Rats; Steroid 17-alpha-Hydroxylase; Testosterone; Physiology; Clinical Biochemistry; Cell BiologyAnabolic AgentsOriginal Research ArticlesNandroloneTestosteroneOriginal Research ArticleTestosteroneAnabolic Agents; Androgens; Animals; Cell Line; Cell Survival; Dose-Response Relationship Drug; Gene Expression Regulation Enzymologic; Leydig Cells; Male; Nandrolone; Phosphoproteins; Rats; Steroid 17-alpha-Hydroxylase; Testosterone; Clinical Biochemistry; Cell Biology; Physiology; Medicine (all)Steroidogenic acute regulatory proteinMedicine (all)Leydig CellsSteroid 17-alpha-HydroxylaseCYP17A1PhosphoproteinAndrogensDrugLuteinizing hormonemedicine.drugAnabolic Agents; Androgens; Animals; Cell Line; Cell Survival; Dose-Response Relationship Drug; Gene Expression Regulation Enzymologic; Leydig Cells; Male; Nandrolone; Phosphoproteins; Rats; Steroid 17-alpha-Hydroxylase; TestosteroneLeydig Cellendocrine systemmedicine.medical_specialtyCell SurvivalBiologyGene Expression Regulation EnzymologicCell LineDose-Response Relationship03 medical and health sciencesDownregulation and upregulationIn vivoInternal medicinemedicineAnimalsDose-Response Relationship DrugAnimalCell BiologyPhosphoproteinsRats030104 developmental biologyEndocrinologyGene Expression RegulationNandroloneAnabolic AgentRatHormone
researchProduct

Redox Status, Dose and Antioxidant Intake in Healthcare Workers Occupationally Exposed to Ionizing Radiation

2020

The purpose of this study was to evaluate the relationship between blood redox status, dose and antioxidant dietary intake of different hospital staff groups exposed to low doses of ionizing radiation (LDIR) (Interventional Radiology and Cardiology, Radiation Oncology, and Nuclear Medicine) and non-exposed. Personal dose equivalent (from last year and cumulative), plasma antioxidant markers (total antioxidant capacity, extracellular superoxide dismutase activity, and glutathione/oxidized glutathione ratio), oxidative stress markers (nitrites and nitrates, and lipid peroxidation) and dietary intake (antioxidant capacity using ORAC values) were collected and analyzed from 28 non-exposed healt…

0301 basic medicineIonizing radiationAntioxidantPhysiologyThiobarbituric acidmedicine.medical_treatmentClinical BiochemistryPhysiologymedicine.disease_causeBiochemistryArticleIonizing radiationLipid peroxidation03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOxygen radical absorbance capacity (ORAC)TBARSMedicineMolecular Biologypersonal dose equivalentPersonal dose equivalentbusiness.industryEquivalent doselcsh:RM1-950Antioxidant-oxidant statusCell BiologyGlutathioneoccupational exposureOccupational exposure030104 developmental biologyantioxidant-oxidant statuslcsh:Therapeutics. Pharmacologychemistryoxygen radical absorbance capacity (ORAC)030220 oncology & carcinogenesisbusinessionizing radiationOxidative stressAntioxidants
researchProduct

Cytokine profile of breast cell lines after different radiation doses

2017

Purpose: Ionizing radiation (IR) treatment activates inflammatory processes causing the release of a great amount of molecules able to affect the cell survival. The aim of this study was to analyze the cytokine signature of conditioned medium produced by non-tumorigenic mammary epithelial cell line MCF10A, as well as MCF7 and MDA-MB-231 breast cancer cell lines, after single high doses of IR in order to understand their role in high radiation response. Materials and methods: We performed a cytokine profile of irradiated conditioned media of MCF10A, MCF7 and MDA-MB-231 cell lines treated with 9 or 23 Gy, by Luminex and ELISA analyses. Results: Overall, our results show that both 9 Gy and 23 …

0301 basic medicineIonizing radiationRadiology Nuclear Medicine and ImagingCell SurvivalCytokine profileBreast NeoplasmsInflammationRadiationRadiation ToleranceIonizing radiation03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerCell Line TumormedicinecytokineHumansskin and connective tissue diseasesCell survivalRadiological and Ultrasound TechnologyChemistrybreast cancer cytokines inflammation Ionizing radiation Breast Neoplasms Cell Line Tumor Cell Survival Culture Media Conditioned Dose-Response Relationship Radiation Humans Phenotype Radiation ToleranceDose-Response Relationship Radiationmedicine.diseasecytokinesDose–response relationship030104 developmental biologyPhenotypeCell cultureinflammation030220 oncology & carcinogenesisCulture Media ConditionedImmunologyCancer researchmedicine.symptomBreast NeoplasmHuman
researchProduct

Comparison of time and dose dependent gene expression and affected pathways in primary human fibroblasts after exposure to ionizing radiation

2020

Abstract Background Exposure to ionizing radiation induces complex stress responses in cells, which can lead to adverse health effects such as cancer. Although a variety of studies investigated gene expression and affected pathways in human fibroblasts after exposure to ionizing radiation, the understanding of underlying mechanisms and biological effects is still incomplete due to different experimental settings and small sample sizes. Therefore, this study aims to identify the time point with the highest number of differentially expressed genes and corresponding pathways in primary human fibroblasts after irradiation at two preselected time points. Methods Fibroblasts from skin biopsies of…

0301 basic medicineIonizing radiationTime FactorsDNA damageCellHigh doseIonizing radiationlcsh:BiochemistryGene-radiation interaction03 medical and health sciences0302 clinical medicineRadiation IonizingGene expressionGeneticsmedicineHumanslcsh:QD415-436IrradiationMolecular BiologyGeneGenetics (clinical)Gene-radiation interaction ; RNA sequencing ; Childhood cancer ; High dose ; Fibroblasts ; Low dose ; Second primary neoplasm ; IPA ; Ionizing radiationCells CulturedChemistryGene Expression Profilinglcsh:RM1-950Second primary neoplasmCancerComputational BiologyRNA sequencingDose-Response Relationship RadiationFibroblastsmedicine.diseaseCell biology030104 developmental biologymedicine.anatomical_structurelcsh:Therapeutics. PharmacologyLow doseGene Expression Regulation030220 oncology & carcinogenesisIPACase-Control StudiesMolecular MedicineSignal transductionChildhood cancerResearch ArticleSignal TransductionMolecular Medicine
researchProduct

A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer

2018

Introduction IMAB362 (Zolbetuximab) is a chimeric monoclonal antibody that binds to Claudin-18.2, a target antigen specific to cancer cells. In vitro, IMAB362 mediates cell death through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity; thus, IMAB362 may serve as a potent, targeted immunotherapeutic agent. Methods This first-in-human phase I study enroled adult patients (N = 15) with advanced gastric or gastro-oesophageal junction cancer into five sequential single dose-escalation cohorts (33, 100, 300, 600, and 1000 mg/m2) following a 3 + 3 design. Safety/tolerability, including determination of maximum tolerated dose and recommended phase II dose, were the pr…

0301 basic medicineMaleCancer Researchmedicine.medical_specialtyTime FactorsEsophageal NeoplasmsMaximum Tolerated Dosemedicine.medical_treatmentMedizinGastroenterologyAntibodies Monoclonal/administration & dosage03 medical and health sciences0302 clinical medicineAntineoplastic Agents ImmunologicalPharmacokineticsAntineoplastic Agents Immunological/administration & dosageStomach NeoplasmsInternal medicineGermanymedicineHumansDrug Dosage CalculationsAdverse effectInfusions IntravenousAgedbusiness.industryCancerAntibodies MonoclonalEsophagogastric Junction/drug effectsImmunotherapyMiddle Agedmedicine.diseaseLatviaddc:030104 developmental biologyTreatment OutcomeOncologyTolerabilityResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisToxicityDisease ProgressionFemaleStomach Neoplasms/drug therapyEsophagogastric JunctionEsophageal Neoplasms/drug therapybusinessProgressive disease
researchProduct

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.

2020

Abstract Ibrutinib, obinutuzumab, and venetoclax demonstrate synergy in preclinical models of mantle cell lymphoma (MCL). OAsIs (NCT02558816), a single-arm multicenter prospective phase 1/2 trial, aimed to determine the maximum tolerated dose of venetoclax in combination with fixed doses of ibrutinib and obinutuzumab, in relapsed MCL patients. At the venetoclax MTD, extension cohorts were opened for relapsed and untreated patients. Safety and efficacy were secondary objectives. Minimal residual disease (MRD) was assessed by allele-specific oligonucleotide quantitative polymerase chain reaction. Between 14 October 2015 and 29 May 2018, 48 patients were enrolled. No dose-limiting toxicity was…

0301 basic medicineMaleNeoplasm Residualmedicine.medical_treatmentImmunoglobulin Variable RegionHematopoietic stem cell transplantationKaplan-Meier EstimateLymphoma Mantle-CellBiochemistryGastroenterologychemistry.chemical_compound0302 clinical medicinePiperidinesObinutuzumabAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesProspective cohort studyAged 80 and overSulfonamidesHematopoietic Stem Cell TransplantationHematologyMiddle AgedCombined Modality TherapyProgression-Free Survival3. Good healthTreatment Outcome030220 oncology & carcinogenesisIbrutinibFemaleImmunoglobulin Heavy Chainsmedicine.medical_specialtyMaximum Tolerated DoseImmunologyAntibodies Monoclonal Humanized03 medical and health sciencesInternal medicinemedicineHumansProgression-free survivalAgedVenetoclaxbusiness.industryAdenineCell Biologymedicine.diseaseBridged Bicyclo Compounds HeterocyclicGenes p53Minimal residual diseaseHematologic Diseases030104 developmental biologychemistryMutationMantle cell lymphomabusinessFollow-Up StudiesBlood
researchProduct